Zhao J, Wu Y, Rong X, Zheng C, Guo J
A Note on Rare Genetic Obesity One further drug, setmelanotide (Imcivree) , is approved by Health Canada, but only for a small group of patients with rare genetic causes of obesity (such as Bardet-Biedl syndrome)
This is one of the most important long-term risks of these medications and is directly addressed by intentional protein timing
The supplement costs a small fraction of an FDA-approved GLP-1 prescription drug that can run as high as $1,000 per month without insurance
In pediatrics, most available studies do not stratify outcomes by sex, underscoring an important knowledge gap and the urgent need for research that addresses sex-specific responses during childhood and adolescence